Somatostatin
- PDF / 169,182 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 29 Downloads / 165 Views
1 S
Lack of efficacy in severe acute pancreatitis: case report In a retrospective study of 980 patients conducted between January 2010 to October 2016, a patient [age and sex not stated] was described, who exhibited lack of efficacy following treatment with somatostatin for severe acute pancreatitis. The patient, who was diagnosed with tumour and obstructive jaundice, underwent a percutaneous placement of self-expandable metallic stent under lidocaine [lidocaine hydrochloride] as a local anaesthesia. Following operation, the patient was followed-up at every 2-day interval. Subsequently, the patient developed severe acute pancreatitis as a complication of operation, and was treated with IV injection of somatostatin 4 mg/day for 14 days. However, the somatostatin treatment showed no effect. Within one day of the operation, the patient died due to severe acute pancreatitis. Yang Y, et al. Incidence and risk factors of pancreatitis in obstructive jaundice patients after percutaneous placement of self-expandable metallic stents. Hepatobiliary and 803519238 Pancreatic Diseases International 19: 473-477, No. 5, Oct 2020. Available from: URL: http://doi.org/10.1016/j.hbpd.2020.03.007
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
